Gyre Therapeutics
GYRE
59 hedge funds and large institutions have $57.1M invested in Gyre Therapeutics in 2026 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 31 increasing their positions, 9 reducing their positions, and 7 closing their positions.
3,835% more capital inflows, than outflows
Capital inflows: $36.8M | Capital outflows: $934K
244% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 9
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
5% more funds holding
Funds holding: 56 → 59 (+3)
4.26% more ownership
Funds ownership: 3.51% → 7.77% (+4.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HSG Holding
Na,
Hong Kong
|
+$25.5M |
| 2 |
Octagon Capital Advisors
New York
|
+$6.5M |
| 3 |
BlackRock
New York
|
+$1.6M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$692K |
| 5 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
+$369K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
-$731K |
| 2 |
Brevan Howard Capital Management
St. Helier,
Jersey
|
-$96.2K |
| 3 |
SBI Securities
Tokyo,
Japan
|
-$27.8K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$25.5K |
| 5 |
Tower Research Capital (TRC)
New York
|
-$22.4K |
GYRE Hedge Fund Activity: Q2 2026 in Review
59 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q2 2026, worth a combined $57.1M — up 140% from $23.8M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new GYRE positions and 7 closed out — a net gain of 4 holders — while 31 added to existing stakes and 9 trimmed.
The largest buyer was HSG Holding, opening a new position worth an estimated $25.5M. The largest seller was Vanguard Capital Management, cutting an estimated $731K.
- 59 institutional investors held Gyre Therapeutics (GYRE) as of Q2 2026, up from 56 in Q1 2026.
- Funds reported $57.1M of Gyre Therapeutics stock for Q2 2026, up 140% quarter-over-quarter.
- 11 funds opened new Gyre Therapeutics positions in Q2 2026 and 7 closed out, a net change of +4 holders.
- The largest Gyre Therapeutics buyer in Q2 2026 was HSG Holding, an estimated $25.5M added.
- The largest Gyre Therapeutics seller in Q2 2026 was Vanguard Capital Management, an estimated $731K sold.
Based on aggregated 13F filings for Q2 2026.